Abivax (AAVXF) Non Operating Income (2023 - 2024)
Abivax (AAVXF) posted Non Operating Income of -$3.53 for Q4 2024, up 83.93% on a QoQ basis from -$21.95 in Q4 2023, and up 83.93% year-over-year from -$1.92 in Q1 2024.
Powered by 
Analysis
Abivax (AAVXF) Non Operating Income (2023 - 2024) Analysis & Trends
Abivax has reported Non Operating Income for 2 years, with the latest figure at -$3.53 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - | - |